INCONTROL MEDICAL INTENSITY SKIN

Subjects with history of kidneys stones.Drug or nondrug treatments of OAB (in the previous 14 days), Concomitant medications that affect detrusor activity.Previous pelvic radiation therapy or previous, current malignant disease of the pelvic organs or having received intravesical injection or electrostimulation in the past 12 months.Significant bladder outflow obstruction.Patients who have underlying urologic cancer.Patients who have severe coagulopathy or liver failure or renal failure.Patients who have severe cardiovascular disease.Patients who have catheterization due to poor voiding function of urine.Patients who have operation, wound or infection around perineum.Lower urinary tract surgery in the last 6 months.History of carcinoma of the urinary tract.Chronic urologic inflammatory condition (Interstitial cystitis, urethral syndrome, painful bladder syndrome).Patients who have other disease: diabetes mellitus, spinal cord injury, stoke history, brain disease and neurogenic disease which can cause OAB.Urinary tract infection (UTI) at screening and recurrent UTI defined as в‰Ґ 3 UTIs in the previous 12 months.Patients would like to sign the informed consent.Patients can understand, obey order and finish the questionnaires.Patients with OAB symptoms including urgency or/and urgency incontinence, urinary frequency and nocturia in the previous 3 months without medical treatments: antimuscarinic or Гџ3 agonist therapy.Patients have a в‰Ґ 3 month history of experiencing Stress Urinary Incontinence (SUI) per week (self reported).Frequency of micturition в‰Ґ 8 times daytime as well as 2 times nighttime, and в‰Ґ 2 episodes of urgency per week.

Therefore improve quality of life and improve social activity. The hypothesis of the present study is LiESWT can decrease inflammatory disorders, increase pelvic floor blood supply, enhanced bladder stem cell activation, Using LiESWT can decrease bladder overactivity, eliminate urinary incontinence and improve stress urinary incontinence (SUI) and overactive bladder (OAB) symptoms. Importantly, the advantages of LiESWT include therapies without medication or surgery, outpatient therapies, short treatment sessions, no anesthesia required, and non-invasive therapy. LiESWT has also been shown to increase vascular endothelial growth factor (VEGF) expression in ischemic tissues in vivo and to promote angiogenesis and functional recovery in models of chronic myocardial ischemia, myocardial infarction, and peripheral artery disease.

INCONTROL MEDICAL INTENSITY SKIN

Generally, LiESWT was used clinically to improve tissue regeneration at tendon-bone junctions, ischemic cardiovascular disorders, skin wound healing, chronic injuries of soft tissues and erectile dysfunction.

Why Should I Register and Submit Results?Д¬linical application of low intensity extracorporeal low energy shock wave therapy (LiESWT) (2000 to 3000 impulses in 0.20-0.25 millijoule/mm2 (mJ/mm2)) initiated wound healing, promoted angiogenesis, reduced the level of oxidative stress, induced the releasing of VEGF, stimulated proliferation and differentiation of stem cells, and resulted in the effect of anti-inflammatory and tissue regeneration.

Incontrol medical intensity